Before you sell to, join or invest in Aviceda Therapeutics, Inc.
MentionFox check on Aviceda Therapeutics, Inc.: only 2 sources on file so far (checked 8 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/aviceda-therapeutics-inc-form-d-24000001
Check Aviceda Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Aviceda Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2024-11-22.
Aviceda Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on November 22, 2024. The filing reports $75M sold. Its industry group is Biotechnology. It names Mohamed Genead (Executive Officer, Director), Michael Tolentino (Executive Officer, Director), Nancy Thomason (Director) (SEC Form D/A, November 22, 2024).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Aviceda Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-11-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Aviceda Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Aviceda Therapeutics, Inc., from the filings we hold.
Leerink Partners LLC received sales compensation on this raise and on 15 other raises we hold, nearest in date first:
Get an email when Aviceda Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Aviceda Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Aviceda Therapeutics, Inc. →Get the full cited report on Aviceda Therapeutics, Inc.
What the filing shows about Aviceda Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aviceda Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Aviceda Therapeutics, Inc.'s address as One Broadway, 14TH Floor, Cambridge, MA 02142.
Saved here on this device in the meantime, so nothing is lost either way.
Amended on 2025-01-13: the offering size changed from $200,000,000 to $207,499,882; the amount sold changed from $0 to $74,999,940; the number of investors changed from 0 to 17. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Aviceda Therapeutics, Inc. See pricing
Aviceda Therapeutics, Inc. is a registered filer with the SEC (CIK 1824762) and has filed since 2023-05-19. 4 filings are on record, the latest on 2025-01-13.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Aviceda Therapeutics, Inc.'s Form D of 2024-11-22 names Mohamed Genead, Michael Tolentino, Nancy Thomason and 7 more as its officers, directors or promoters.
Its new offerings report $34.51M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 763 filings in Biotechnology, totalled by week.
Mohamed Genead is named as Executive Officer and Director on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
Michael Tolentino is named as Executive Officer and Director on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
Nancy Thomason is named as Director on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
Christoph Adams is named as Director on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
David Guyer is named as Director on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
Jay Woods is named as Director on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
Erin Lavelle is named as Director on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
David Callanan is named as Executive Officer on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
Tarek Hassan is named as Executive Officer on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
Derek Kunimoto is named as Executive Officer on the Form D that Aviceda Therapeutics, Inc. filed with the SEC on 22 November 2024, one of 10 people that filing names.
10 people named on the filing — 5 holding an executive role and 5 as directors only.
Named as of the 2024-11-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Aviceda Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aviceda Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aviceda Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Aviceda Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Aviceda Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Aviceda Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/aviceda-therapeutics-inc-form-d-24000001